The funding was granted by CTI Life Sciences Fund (CTI), Advanced Biotechnologies Venture Fund (ABVF) and by several existing private shareholders.
Zymeworks president and CEO said the investment will allow them to further advance Azymetric, AlbuCORE and EFECT platforms, to accelerate the development of their protein therapeutics pipeline, and to ultimately make a difference in the lives of patients across the globe.